SG Americas Securities
NBIX icon

SG Americas Securities’s Neurocrine Biosciences NBIX Stock Holding History

SG Americas Securities’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-55,000
Closed -$187K – 3187
2020
Q2 		$187K Buy
55,000
+8,100
+17% +$895K ﹤0.01% 2911
2020
Q1 		$333K Buy
+46,900
New +$4.59M ﹤0.01% 2149

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SG Americas Securities's NBIX Position: Q1 2026 in Review

SG Americas Securities reduced its Neurocrine Biosciences (NBIX) stake by 56% in Q1 2026, selling an estimated $9.99M and leaving 59,267 shares worth $7.81M. The position accounts for 0.01% of the portfolio, ranked #879.

SG Americas Securities first reported a position in NBIX in Q2 2013 and has held it in 42 quarters since. The position peaked at $19.4M in Q1 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • SG Americas Securities held 59,267 shares of Neurocrine Biosciences worth $7.81M as of Q1 2026.
  • SG Americas Securities sold 75,263 Neurocrine Biosciences shares in Q1 2026, an estimated $9.99M.
  • Neurocrine Biosciences made up 0.01% of SG Americas Securities's portfolio in Q1 2026, its #879 holding.
  • SG Americas Securities first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 42 quarters since.
  • SG Americas Securities's Neurocrine Biosciences position peaked at $19.4M in Q1 2025.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.